文献速递类风湿关节炎

低炎症性难治性类风湿关节炎中b/tsDMARD转换的真实世界有效性:FIRST登记研究

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.
PubMed 文献 · RMD Open · 2026-02-05

基于多中心FIRST登记研究,纳入2013年8月至2024年3月间难治性类风湿关节炎(D2T RA)患者,其中低炎症性D2T RA定义为肿胀28关节计数≤1且C反应蛋白<10 mg/L。在低炎症性D2T RA中,倾向评分匹配后转换b/tsDMARD组(n=15)较非转换组(n=30)在6个月时CDAI和疼痛改善更显著,提示低炎症状态本身不应排除治疗强化。

要点

  • 低炎症性D2T RA患者中仅16.8%接受b/tsDMARD转换,远低于炎症性D2T RA的76.4%。
  • 倾向评分匹配后,转换组CDAI改善-6.6 vs 非转换组-2.2,疼痛改善-15.3 vs -3.4(均p<0.05)。
  • 即使超声灰度≤1且能量多普勒=0的低活动患者,转换b/tsDMARD后CDAI仍从16.8降至9.7。

核心结论

  • 部分低炎症性D2T RA患者可从b/tsDMARD转换中获益,低炎症状态本身不应排除治疗强化。

研究设计与样本

  • 多中心FIRST登记研究,2013年8月至2024年3月,3519例患者中457例符合D2T RA标准,173例为低炎症性D2T RA。
  • 低炎症性D2T RA定义为肿胀28关节计数≤1且C反应蛋白<10 mg/L。
  • 在低炎症性D2T RA中比较b/tsDMARD转换组与非转换组,主要结局为6个月CDAI变化。

主要发现

  • 低炎症性D2T RA较炎症性D2T RA病程更短(127.4 vs 146.4个月),甲氨蝶呤剂量更低(9.2 vs 10.5 mg/周),糖皮质激素剂量更低(4.3 vs 5.2 mg/天)。
  • 低炎症性D2T RA中纤维肌痛(2.9% vs 1.4%)和心理障碍(5.2% vs 1.8%)比例更高。
  • 低炎症性D2T RA接受b/tsDMARD转换的比例为29/173(16.8%),低于炎症性D2T RA的217/284(76.4%)。
  • 倾向评分匹配后,转换组(n=15)CDAI改善-6.6 vs 非转换组(n=30)-2.2,疼痛改善-15.3 vs -3.4,均p<0.05。
  • 超声低活动(灰度≤1,能量多普勒=0)患者中,b/tsDMARD转换后CDAI从16.8降至9.7。

关键数值与推荐

  • 低炎症性D2T RA定义:肿胀28关节计数≤1且C反应蛋白<10 mg/L。
  • 主要结局:6个月CDAI变化。
  • 倾向评分匹配分析中转换组n=15,非转换组n=30。

临床怎么用

  • 对低炎症性D2T RA患者,不应仅因炎症指标低而排除b/tsDMARD转换治疗。
  • 转换b/tsDMARD可能改善低炎症性D2T RA患者的疾病活动和疼痛。
  • 需注意低炎症性D2T RA患者中纤维肌痛和心理障碍比例较高,应综合评估。

局限性

  • 倾向评分匹配后样本量较小(转换组n=15,非转换组n=30)。
  • 为观察性登记研究,可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effectiveness of switching biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with low-inflammatory difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: Using the multicentre FIRST registry, we identified D2T RA between August 2013 and March 2024. Low-inflammatory D2T RA was defined as a swollen 28-joint count ≤1 and C-reactive protein <10 mg/L. In the low-inflammatory D2T RA group, we compared those who underwent b/tsDMARD switching (the switch group) with the non-switch group. The primary outcome was the 6-month change in Clinical Disease Activity Index (CDAI). RESULTS: Among 3519 patients, 457 fulfilled the D2T RA criteria, and 173 were low-inflammatory D2T RA. Compared with inflammatory D2T RA, these patients had a shorter disease duration (127.4 vs 146.4 months), lower methotrexate (9.2 vs 10.5 mg/week) and glucocorticoid doses (4.3 vs 5.2 mg/day), and higher rates of fibromyalgia (2.9% vs 1.4%) and psychological disorders (5.2% vs 1.8%). The proportion receiving b/tsDMARD switching was lower in low-inflammatory than in inflammatory D2T RA (29/173 (16.8%) vs 217/284 (76.4%)). In the propensity score-matched analysis, the switch group (n=15) showed greater improvements in CDAI and pain than the non-switch group (n=30) (-6.6 vs -2.2, -15.3 vs -3.4, both p<0.05). Even among patients with low-grade sonographic activity (greyscale ≤1, power Doppler=0), b/tsDMARD switching improved CDAI (16.8 to 9.7). CONCLUSIONS: A subset of patients with low-inflammatory D2T RA may benefit from b/tsDMARD switching, indicating that low-inflammatory status alone should not preclude consideration of treatment intensification.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sakai H, Sonomoto K, Nakayamada S, et al. Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry. RMD Open. 2026. PMID: 41644272. doi:10.1136/rmdopen-2025-006513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。